Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 8

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1A
Chunk 8
---

development stage. Moreover, we cannot be certain that our research and development efforts will be successful or, if successful, that
our potential treatments will ever be approved for sale to generate commercial revenues. Our therapeutic pipeline includes cell, gene
and immunotherapy involving genetically modified cells targeted to treat cancer, and we rely on third parties under contract in the development
of product candidates in our pipeline. There is no guarantee that we will be able to manage and fund the development of a pipeline with
multiple target conditions, nor that third parties will meet their obligations to us in connection with our research and development.
We and certain third parties, on which we rely, have no relevant operating history upon which an evaluation of our performance and prospects
can be made. We are subject to all of the business risks associated with a new enterprise, including, but not limited to, risks of unforeseen
capital requirements, failure of treatments either in non-clinical testing or in clinical trials, failure to establish business relationships,
failure of our third parties to meet their obligations to us and competitive disadvantages against larger and more established companies.
If we fail to become profitable, we may suspend or cease operations.

Renovaro
Cube and BioSymetrics are artificial intelligence (“AI”)-driven healthcare technology companies operating in a rapidly evolving
field with a limited operating history, which makes it difficult to evaluate their current business and predict Renovaro Cube’s
future performance.

Renovaro
Cube and BioSymetrics are AI-driven healthcare technology companies operating in a rapidly evolving field and, having commenced operations
in 2013 and 2017, respectively, have a limited operating history. Renovaro Cube shifted its business from the financial technology
(or FinTech) industry to cancer diagnostics in 2018 and does not have a commercial product for sale. It has never generated any revenue
relating to its cancer diagnostics AI platform. Renovaro Cube’s short operating history makes any assessment of its current business
or future success and viability subject to significant uncertainty. BioSymetrics does have a history of deployment of a commercial AI-based
biotechnology platform and has had previous revenue generation, however the same risk regarding future performance applies. We expect
to encounter risks and difficulties, including those frequently experienced by early-stage companies in rapidly evolving fields.
If we do not address these risks and difficulties successfully, our business will suffer.

23

Renovaro
Cube and BioSymetrics have a history of net losses and anticipates that they may continue to incur net